KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Acquisitions & Divestments: 2013-2024

Historic Change in Acquisitions & Divestments for Travere Therapeutics (TVTX) over the last 12 years, with Dec 2024 value amounting to $326.3 million.

  • Travere Therapeutics' Change in Acquisitions & Divestments rose 96.29% to $106.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.2 million, marking a year-over-year decrease of 7.80%. This contributed to the annual value of $326.3 million for FY2024, which is 2.46% down from last year.
  • Latest data reveals that Travere Therapeutics reported Change in Acquisitions & Divestments of $326.3 million as of FY2024, which was down 2.46% from $334.6 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Change in Acquisitions & Divestments ranged from a high of $433.6 million in FY2021 and a low of $273.5 million during FY2020.
  • Its 3-year average for Change in Acquisitions & Divestments is $347.6 million, with a median of $334.6 million in 2023.
  • Per our database at Business Quant, Travere Therapeutics' Change in Acquisitions & Divestments skyrocketed by 58.55% in 2021 and then fell by 12.41% in 2023.
  • Over the past 5 years, Travere Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $273.5 million in 2020, then skyrocketed by 58.55% to $433.6 million in 2021, then declined by 11.90% to $382.0 million in 2022, then decreased by 12.41% to $334.6 million in 2023, then dropped by 2.46% to $326.3 million in 2024.